Antibiotics after bladder botox: infection prevention or not?
NCT ID NCT04444440
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether taking the antibiotic ciprofloxacin for three days after bladder Botox injections reduces the risk of urinary tract infections in women with overactive bladder. About 202 women will be randomly assigned to receive either the antibiotic or a placebo pill. The main goal is to see if fewer infections occur in the antibiotic group over six weeks.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Ciprofloxacin (antibiotic)
- What this could lead to
- If it works, this could show that a short course of antibiotics after bladder Botox reduces the chance of urinary tract infections in women.
- What could go wrong
- This is a Phase 4 trial, but it only looks at infection rates, not long-term safety. Antibiotics can cause side effects like nausea, and may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 202 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2021
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with idiopathic OAB diagnosed clinically who have failed medical management * Female * Age ≥ 18 Exclusion Criteria: * Patients with neurogenic OAB (OAB with potential underlying neurologic cause - multiple sclerosis, spinal cord injury, Parkinson's disease, other) * Contraindication to injection of Botox - hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation, current urinary tract infection, symptomatic urinary retention or PVR \> 200 mL, unwillingness or inability to initiate CIC post-treatment if required. * Contraindication to oral Ciprofloxacin - hypersensitivity or allergy to Ciprofloxacin or other fluoroquinolone, concurrently taking Tizanidine or Agomelatine.14 * Active antibiotic therapy for any indication at the time of Botox injection - increased risk of adverse reaction with combining antibiotics, reduced risk of UTI with additional antibiotic. * Male * Age \< 18 * Pregnant and/or breastfeeding
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Idiopathic overactive bladder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Urogynecology Clinic - Royal Alexandra Hospital
RECRUITINGEdmonton, Alberta, T5H3V9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.